COVID-19_YHLO

YHLO

YHLO

Language

Reproductive Health

Home page

2024/06/05

NC-Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents

2024/06/05

AR-Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases

2024/06/05

JTOEfficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer A Prospective Study Supporting a Third Dose in Patients With Mini

2024/06/05

JHO-Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls

2024/06/05

STTT-SARS-CoV-2-specific immune response in COVID-19 convalescent individuals

2024/06/05

Leu-Covid-19 in patients with chronic lymphocytic leukemia clinical outcome and B- and T-cell immunity during 13 months in consecutive patients

2024/06/05

STTT-Differential immune responses in pregnant patients recovered from COVID-19

2024/06/05

AIM-Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19 A Retrospective Study

2024/06/05

JACI-Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19) A multicenter, single-blind, randomized controlled trial

2024/06/05

Cell Re Serosurvey of SARS-CoV-2 among hospital visitors in China

< 1 2 3 4 >

YHLO

Home
Products
- CLIA
  - Analyzers
  - Reagents
- Chemistry
- TLA
- LIA
- ESR
Pubilcations
- Autoimmunity
- Reproductive Health
- Diabetes
- Liver Disease
- Infection
- COVID-19
- ESR
- Others
News
- YHLO News
About YHLO
Contact us
- Career
- Service

Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China

Tel: +86 755 26601910

Email: marketing@szyhlo.com

youtube

instagram

wechat

wechat

Copyright© 2024 Shenzhen YHLO Biotech Co., Ltd.

Powered by 300.cn | SEO | Business License

8

Email

marketing@szyhlo.com

9

Tel

+86 755 26601910